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T cell stimulation via glucocorticoid-induced tumor necrosis factor receptor family–related 
protein (GITR) can evoke effective tumor immunity. A single administration of agonistic anti-
GITR monoclonal antibody (mAb) to tumor-bearing mice intravenously or directly into tumors 
provoked potent tumor-specific immunity and eradicated established tumors without eliciting 
overt autoimmune disease. A large number of CD4
 
 
 
 and CD8
 
 
 
 T cells, including interferon 
(IFN)-
 
 
 
–secreting cells, infiltrated regressing tumors. Tumor-specific IFN-
 
 
 
–secreting CD4
 
 
 
 
and CD8
 
 
 
 T cells also increased in the spleen. The treatment led to tumor rejection in IFN-
 
 
 
–
intact mice but not IFN-
 
 
 
–deficient mice. Furthermore, coadministration of anti-GITR and 
anti–CTLA-4 mAbs had a synergistic effect, leading to eradication of more advanced tumors. 
In contrast, coadministration of anti-CD25 and anti-GITR mAbs was less effective than anti-
GITR treatment alone, because anti-CD25 depleted both CD25
 
 
 
-activated effector T cells and 
CD25
 
 
 
CD4
 
 
 
 naturally occurring regulatory T (T reg) cells. Importantly, CD4
 
 
 
 T cells 
expressing the T reg–specific transcription factor Foxp3 predominantly infiltrated growing 
tumors in control mice, indicating that tumor-infiltrating natural Foxp3
 
 
 
CD25
 
 
 
CD4
 
 
 
 T reg 
cells may hamper the development of effective tumor immunity. Taken together, T cell 
stimulation through GITR attenuates T reg–mediated suppression or enhances tumor-killing 
by CD4
 
 
 
 and CD8
 
 
 
 effector T cells, including those secreting IFN-
 
 
 
, or both. Agonistic anti-
GITR mAb is therefore instrumental in treating advanced cancers.
 
There is substantial evidence that cancer patients
harbor tumor-reactive T cells, although their
reactivity or number is usually insufficient to
eradicate tumors (1). How such tumor-reactive
T cells can be sufficiently activated and ex-
panded to cure established tumors is a key issue
for devising effective immunotherapy for cancer
(2). One way of achieving this is to breach the
mechanisms of peripheral self-tolerance that may
hamper the activation of T cells reactive with
tumor-associated antigens, many of which are
normal self-antigens (1). There is accumulating
evidence that naturally occurring CD25
 
 
 
CD4
 
 
 
regulatory T (T reg) cells not only engage in
the maintenance of immunologic self-tolerance
in the periphery but also impede immuno-
surveillance against autologous tumor cells (3).
For example, depletion of CD25
 
 
 
CD4
 
 
 
 T
cells by administration of anti-CD25 mAb before
tumor challenge provokes effective immune
responses to syngeneic tumors in otherwise
nonresponding animals (4–6). In humans,
tumor-reactive T cells can be efficiently ex-
panded in vitro when CD25
 
 
 
CD4
 
 
 
 T cells
are depleted from PBMCs before stimulation
with tumor-derived peptide (7). A key issue in
tumor immunology is then to determine how
effective immune responses against advanced
tumors can be provoked by attenuating T
reg–mediated suppression and, concomitantly,
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stimulating tumor-reactive T cells present in cancer-bear-
ing hosts.
CD25
 
 
 
CD4
 
 
 
 natural T reg cells constitutively express the
transcription factor Foxp3, cytotoxic T lymphocyte-associated
protein 4 (CTLA-4), and glucocorticoid-induced TNF recep-
tor family-related protein (GITR) (TNFRSF18) (8–15). They
express GITR at higher levels than other T cells, although
both T reg and non–T reg cells up-regulate its expression upon
activation (11, 12). In vitro studies have shown that cross-link-
ing of GITR, not its blockade, by a specific mAb, together
with TCR stimulation, abrogates CD25
 
 
 
CD4
 
 
 
 T cell–medi-
ated suppression, triggers proliferation of T reg cells in the
presence of interleukin 2, and exhibits costimulatory activity
for TCR-stimulated T cell activation (11, 12, 16–19). Admin-
istration of the mAb to neonatal mice can indeed break
self-tolerance and elicit autoimmune disease (11). This GITR-
mediated attenuation of suppression and costimulation of effec-
tor T cells synergistically enhanced in vivo antigen-specific im-
mune responses such as antiviral immunity, allograft rejection,
and graft-versus-host reaction (20–22). We examined the im-
munostimulatory activity of agonistic anti-GITR mAb to pro-
voke effective tumor immunity in mice with advanced tumors.
We also assessed local and systemic effects of mAb on tumor-
targeting effector T cells and Foxp3-expressing T reg cells; its
possible synergy with other mAbs, such as anti–CTLA-4, to
further enhance tumor immunity; and possible autoimmune-
inducing effects of these mAbs in treated animals.
 
RESULTS AND DISCUSSION
Eradication of established tumors by agonistic anti-GITR 
mAb but not by cell-depleting anti-CD25 mAb
 
DTA-1 is a rat mAb of IgG2b isotype and is incapable of
depleting GITR-expressing cells in vivo (Fig. S1 A, avail-
able at http://www.jem.org/cgi/content/full/jem.20050940/
DC1) (11). Meth A, a BALB/c-derived fibrosarcoma cell
line, does not express GITR—in contrast with hemato-
poietic tumor lines, many of which express GITR (Fig. S1
B)—and DTA-1 treatment did not affect the growth of
Meth A in athymic nude mice (Fig. S1 C). To determine
whether DTA-1 can evoke effective tumor immunity, we
injected 500 
 
 
 
g of DTA-1 intravenously on various days
after intradermal inoculation of Meth A to normal BALB/c
mice (Fig. 1 A). One-shot DTA-1 injection between days
0 and 12 after tumor inoculation led to tumor regression.
The injection on day 8, when tumors were already palpa-
ble, was most effective, and nearly 90% of such mice re-
jected tumors. As for dose response, 100 or 20 
 
 
 
g DTA-1
injection on day 8 led to tumor eradication in 70% (4/7)
Figure 1. Tumor immunity induced by anti-GITR mAb treatment. (A) 
BALB/c mice 8–10 wk of age were inoculated intradermally with 2   
105 Meth A on their back on day 0. Five hundred micrograms of DTA-1, 
PC61, or control rat IgG was injected intravenously on the indicated 
days, and the tumor size of each mouse was monitored every other 
day. (B) BALB/c mice were intradermally inoculated with 105 Colon 26 
cells on day 0 and injected intravenously with 500  g DTA-1 on day 8. 
Control mice were injected with rat IgG on day 8. (C) BALB/c mice that 
had completely rejected Meth A following DTA-1 treatment on day 8 
were intradermally inoculated on day 70 with a 10-fold larger dose of 
Meth A (2 106 cells) and Colon 26 (1 105 cells) on either side of the 
back, and monitored for tumor growth. *P   0.001 via one-sided Fisher 
exact probability test. Results are representative of three independent 
experiments. 
JEM VOL. 202, October 3, 2005
 
887
 
BRIEF DEFINITIVE REPORT
 
and 14% (1/7) of mice, respectively. Multiple injections
were more effective than a single injection (unpublished
data). The results contrasted with the antitumor effect of
PC61 anti-CD25 mAb, which is of the rat IgG1 isotype
and cell-depleting in vivo (4, 5) (Fig. S1 A); that is, PC61
injection 4 d before tumor inoculation was effective in
provoking tumor regression, whereas injection on day 0 or
thereafter was ineffective (Fig. 1 A).
Figure 2. Tumor infiltration of CD4  and CD8  T cells, IFN- –secret-
ing cells, and Foxp3-expressing T reg cells. (A) Mice were treated with 
either DTA-1 or rat IgG on day 8 after tumor inoculation and their tumor 
tissues were taken on day 18 and stained with anti-CD4 or anti-CD8 
(green), anti-Foxp3 and Alexa633-anti–rabbit IgG (blue), and POPO-3 iodide 
for nuclear staining (red), hence purple nuclear staining of Foxp3-expressing 
cells (arrows). Scale bars: 20  m. (B) The number of each T cell population 
per visual field (200   200  m) was counted under a microscope, and the 
average numbers per 1 mm2 in five sections of each tumor (n   3 on each 
time point) obtained on the indicated days are shown. (C) RNA was extracted 
from each tumor tissue (n   5–8) obtained on indicated days after tumor 
inoculation. With each specimen, expression levels of mRNA for CD3, CD4, 
CD8, IFN- , CD25, Foxp3, and HPRT were assessed by quantitative real-time 
PCR, and standardized with HPRT expression levels (a–f). Ordinates are 
arbitrary units. *P   0.05 via two-sided t test. (D) Tumor-infiltrating cells in 
DTA-1– or IgG-treated mice on day 18 after tumor inoculation, as in (A), were 
stained with anti-Foxp3 and anti-CD25, and gated for CD4  or CD8  cells. 
Results are representative of three independent experiments. 
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DTA-1 injection on day 8 also led to regression of Co-
lon 26, a GITR-nonexpressing BALB/c-derived rectal car-
cinoma cell line, at a significant rate (Fig. 1 B). The treat-
ment was similarly effective on other tumor lines, including
GITR-expressing hematopoietic tumor lines (unpublished
data). It was much less effective, however, on other aggres-
sive tumor lines such as B16 melanoma in B6 mice (unpub-
lished data), although DTA-1 treatment of B16 could induce
effective concomitant immunity (23).
Once DTA-1–treated BALB/c mice rejected Meth A, they
rapidly rejected a subsequent challenge with a 10-fold larger
dose of Meth A but failed to reject Colon 26 inoculated at the
same time at another site even at the cell dose leading to tumor
rejection after anti-GITR treatment (Fig. 1 C), indicating that
these mice had become specifically immune to Meth A.
Thus, DTA-1 treatment of tumor-bearing mice can
evoke tumor-specific immunity that is sufficiently potent to
eradicate established tumors.
 
Intratumor infiltration of CD4
 
 
 
 and CD8
 
 
 
 T cells 
after anti-GITR treatment and predominant infiltration 
of Foxp3
 
 
 
CD4
 
 
 
 T cells in control tumors
 
Immunohistochemical characterization of T cells in Meth A
tumors in BALB/c mice treated with DTA-1 on day 8 re-
vealed a large number of infiltrating CD4
 
 
 
 and CD8
 
 
 
 T
cells (Fig. 2, A and B). In contrast, a much smaller number of
CD4
 
 
 
 or CD8
 
 
 
 T cells infiltrated growing tumors in control
mice; the majority of these infiltrating CD4
 
 
 
 cells expressed
Foxp3, especially in the early days after tumor inoculation.
Quantitative assessment of messenger RNA (mRNA)
encoding various genes by real-time polymerase chain re-
action (PCR) revealed that messages for CD3
 
 
 
, CD4
 
 
 
,
CD8
 
 
 
, CD25
 
 
 
, and IFN-
 
 
 
 
 
 cells per tumor volume were
significantly higher in DTA-1–treated tumors than controls
(Fig. 2 C). In contrast, Foxp3 message was higher in con-
trol tumors in the early phase of tumor growth, showing a
good correlation between the number (Fig. 2 B) and
mRNA message (Fig. 2, C–F). The ratios of the messages
for Foxp3 to CD3 were also much higher in growing tu-
mors of control mice than in DTA-treated tumors, even in
the later phase (Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20050940/DC1). Intracellular stain-
ing of the Foxp3 protein at a single cell level also revealed
that, on day 18 after tumor inoculation, Foxp3
 
 
 
 cells were
lower in ratio among tumor-infiltrating CD4
 
 
 
 T cells in
DTA-1–treated mice compared with control mice, whereas
Foxp3
 
 
 
CD25
 
 
 
 cells were much higher in the former.
CD25
 
 
 
CD8
 
 
 
 cells also infiltrated to a much higher ratio in
the former.
Taken together, these results indicate that DTA-1 treat-
ment induces tumor infiltration of CD4
 
 
 
 and CD8
 
 
 
 T cells,
including activated CD25
 
 
 
 T cells and IFN-
 
 
 
–forming cells,
whereas Foxp3
 
 
 
CD25
 
 
 
CD4
 
 
 
 T reg cells predominantly in-
filtrate nontreated tumors without much accompanying in-
filtration of activated T cells.
 
Requirement of IFN-
 
 
 
 for tumor eradication 
after anti-GITR treatment
 
To determine whether DTA-1 treatment of tumor-bearing
mice induces IFN-
 
 
 
–secreting cells in the spleen as well, spleen
cells from BALB/c mice either Meth A–inoculated or noninoc-
ulated and subsequently DTA-1–treated or nontreated were
cultured in vitro with or without Meth A for 18 h, and the
Figure 3. Requirement of IFN- –secreting effector T cells for tumor 
rejection in anti-GITR mAb–treated mice. (A) Whole splenocytes from 
four groups either Meth A–inoculated or not on day 0, or DTA-1–treated or 
not on day 8 were taken on day 11 and 17, and cultured with or without 
Meth A for 18 h. The numbers of IFN- –secreting cells were determined by 
ELISPOT assay. Data are represented as the mean   SD of 3 mice each. 
Statistical analyses were performed using a two-sided t test. (B) CD4 , 
CD8 , and CD4 CD8  splenic T cells from Meth A–inoculated and DTA-1–
treated mice (n   4) were prepared on day 17, cultured with or without 
Meth A, and assessed for the number of IFN- –secreting cells. Data are 
shown as the mean   SD of triplicate wells. (C) 6–8-wk-old normal naive 
BALB/c mice or IFN- –deficient mice were inoculated with 2   105 Meth A 
intradermally on their back on day 0 and injected intravenously with 500 
 g of DTA-1 on day 8. *P   0.04 via one-sided Fisher exact probability test.JEM VOL. 202, October 3, 2005 889
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number of IFN- –secreting cells was assessed (Fig. 3 A).
Spleens from Meth A–inoculated DTA-1–treated mice devel-
oped significantly larger numbers of IFN- –secreting cells than
those from Meth A–inoculated but DTA-1–nontreated mice
whether or not the spleen cells were stimulated in vitro with
Meth A. These IFN- –secreting cells appeared to be tumor-
specific, because in vitro stimulation with other tumor cells
failed to enhance IFN-  secretion by Meth-A/DTA-1–treated
mouse spleen cells (Fig. S3, available at http://www.jem.org/
cgi/content/full/jem.20050940/DC1); they were CD4  or
CD8 , but not CD4  or CD8  (Fig. 3 B). Importantly, DTA-1
treatment alone failed to induce them, indicating requirement
of antigen sensitization for their development. Furthermore,
IFN- –intact BALB/c mice treated with DTA-1 on day 8 re-
jected tumors, whereas similarly treated IFN- –deficient
BALB/c mice did not (Fig. 3 C). These results collectively indi-
cate that DTA-1 treatment increases the number of tumor-spe-
cific CD4  and CD8  T cells secreting IFN- , which appears
to be indispensable for tumor rejection in this system (24, 25).
Given a variety of antitumor activities of IFN-  through pro-
moting innate and adaptive immune responses (26), further
study is required to determine how natural T reg cells physio-
logically control the development of IFN- –secreting tumor-
specific effector T cells.
Eradication of advanced tumors by a combination 
of anti-GITR and anti–CTLA-4 treatment or intratumor 
injection of anti-GITR
As reported previously and shown in Fig. 1, administration of
anti-CD25 and anti–CTLA-4 mAbs can enhance tumor im-
munity (4–6). Coadministration of DTA-1 and PC61 on day
8, however, reduced the tumor-eradicating efficacy of DTA-1,
indicating that PC61 depletes CD25  activated effector T
cells as well as natural CD25 CD4  T reg cells (Fig. 4 A).
This correlates with the infiltration of both populations into
tumors (Fig. 2) and successful tumor rejection only by PC61
treatment before tumor inoculation, but not after (Fig. 1 A).
In contrast, coadministration of DTA-1 and 4F10—a nonde-
pleting hamster anti–CTLA-4 mAb of the IgG isotype (8,
27)—on day 12 when either mAb alone was only marginally
effective for tumor eradication successfully induced tumor re-
gression in a significant number of mice (Fig. 4 B). In addi-
tion, an intratumor injection of a small dose (50  g) of DTA-1
on day 12 was highly effective in tumor rejection (Fig. 4 C).
Thus anti–CTLA-4 is synergistic with anti-GITR in provok-
ing tumor immunity, leading to eradication of more advanced
tumors. Furthermore, local as well as systemic administration
of DTA-1 is effective in evoking tumor immunity.
Failure to elicit overt autoimmune disease by anti-GITR 
mAb treatment
As previously shown, neonatal injection of 1 mg 4F10 or DTA-1
on day 10 and 20 after birth can induce histologically and se-
rologically overt autoimmune disease (e.g., autoimmune gastri-
tis accompanying antiparietal cell autoantibody in BALB/c
mice) (10, 11). In the present experiments, administration of an
equivalent amount of DTA-1, or a mixture of DTA-1 and
4F10, to adult BALB/c mice induced potent tumor immunity
Figure 4. Synergistic antitumor effect of anti-GITR and anti-CTLA-4, 
but not anti-GITR and anti-CD25. (A) BALB/c mice inoculated intradermally 
with 2   105 Meth A were injected intravenously on day 8 with 500  g 
DTA-1, 500  g PC61, a mixture of the two, or 500  g rat IgG. (B) Tumor-
inoculated BALB/c mice were similarly injected on day 12 with 500  g 
DTA-1, 500  g 4F10, or a mixture of the two. (C) Tumor inoculated BALB/c 
mice received an intratumor injection of 50  g of DTA-1 or rat IgG in 10 
 L on day 12 after intradermal inoculation of 2   105 Meth A. *P   0.001 
via one-sided Fisher exact probability test. Results are representative of 
three independent experiments.
Figure 5. No overt autoimmune disease after mAb treatment. BALB/c 
mice treated as shown in Figs. 1 and 4, and those that survived indicated 
days were serologically and histologically assessed for the development of 
autoimmune gastritis and circulating antiparietal cell autoantibody. In all 
cases, there was a histologically intact gastric mucosa.TUMOR IMMUNITY INDUCED BY GITR STIMULATION | Ko et al. 890
but failed to produce histologically evident autoimmune gastritis
or other autoimmune diseases, although the treated mice, espe-
cially those surviving  3 mo, developed low to moderate titers
of antiparietal cell autoantibody (Fig. 5). Intratumor inoculation
proved weaker in the induction of autoantibodies, with hardly
any being detectable.
The present findings have the following implications. First,
agonistic GITR antibody can provoke potent tumor-specific
immunity in tumor-bearing mice. Although the precise molec-
ular mechanism of this potentiation remains to be determined,
it is likely that, in the presence of antigenic stimulation, the anti-
body attenuates T reg–mediated suppression, enhances the ac-
tivity of effector T cells to the degree sufficient to overcome the
suppression, renders them resistant to the suppression, or exerts
a combination of these effects (11, 12, 16–19). Anti–CTLA-4,
especially blocking antibody, appears to have a similar effect;
that is, attenuation of T reg–mediated suppression by blocking
the activation of T reg cells, enhancement of effector activity by
blocking negative signal to effector T cells, or both (8–10, 27,
28). These mAbs can therefore act synergistically in enhancing
immune responses such as tumor immunity. Second, Foxp3-
expressing CD25 CD4  natural T reg cells may preferentially
infiltrate into tumors and impede antitumor immune responses
in the tumors, presumably in the regional lymph nodes and
spleen (29). Given the high self-reactivity of T reg cells, they are
recruited because they recognize not only tumor-associated an-
tigens but also normal self-antigens released from malignant or
normal cells damaged in the tumor (3). Monitoring such tu-
mor-infiltrating Foxp3  T reg cells is of help in assessing the sta-
tus of host tumor immunity. Third, anti-GITR and, for that
matter, anti-CTLA-4 treatment, both of which are potentially
capable of triggering autoimmunity, can evoke effective tumor
immunity without overt autoimmune disease. This differential
effect mainly depends on the dose of agonistic anti-GITR anti-
body, the route (systemic or local) of administration, the dura-
tion of the treatment, the age of the treated host, and its genetic
susceptibility to autoimmune disease (3, 30). Practically, a com-
bination of tumor vaccination with local manipulation of T reg
cells, for example, via intratumor inoculation of agonistic anti-
GITR mAb or immunization with tumor-derived antigens
along with the mAb, may make the current cancer immuno-
therapy more efficacious without deleterious autoimmunity.
The approach used here could also potentially be employed for
effective vaccination against microbes.
MATERIALS AND METHODS
Mice. Female BALB/c mice 8–10 wk of age were purchased from Japan
SLC. BALB/c IFN-  /  mice were purchased from The Jackson Laboratory.
They were maintained in our animal facility and treated in accordance with
the guidelines for animal care approved by the Institute for Frontier Medical
Sciences, Kyoto University. Tumor-inoculated mice were killed when aver-
age tumor diameters reached 20 mm or there was no tendency of tumor re-
gression 30 d after tumor inoculation.
Tumor cells. Meth A was a gift from E. Nakayama (Okayama University,
Okayama, Japan). Colon 26 was obtained from Cell Resource Center for
Biomedical Research, Tohoku University.
Antibodies. FITC–anti-CD25 (7D4) and anti–CD4-PE were purchased
from PharMingen. Anti-CD25 (PC61) (rat IgG1) secreting hybridoma was
purchased from American Type Culture Collection. The hybridoma cells se-
creting anti-CTLA-4 mAb (UC10-4F10-11) were a gift from J. Bluestone
(University of California, San Francisco, CA). R-PE-Cy5-conjugated strepta-
vidin (Dako/Japan) was used as the secondary reagent for biotinylated anti-
bodies. PC61, DTA-1, and 4F10 were purified from ascites of SCID mice by
40% ammonium sulfate precipitation twice. DTA-1 was subsequently puri-
fied by protein G column (GE Healthcare). Purified rat IgG and hamster IgG
were purchased from Sigma and Cappel, respectively. Rabbit anti-mouse
Foxp3 was prepared by immunizing a rabbit with Foxp3-transfected WEHI
cells (Fig. S4, available at http://www.jem.org/cgi/content/full/jem.20050940/
DC1). PE-labeled anti–mouse Foxp3 mAb was purchased from e-BioScience,
and used according to the manufacturer’s instructions.
Serologic analysis and histology. Detailed descriptions of the ELISA
for detecting autoantibodies against the gastric parietal cell antigens was
previously described (12). IFN-  ELISPOT assay was performed using the
Cytokine ELISPOT set (BD Biosciences) according to the manufac-
turer’s instruction. 5   105 freshly isolated whole splenocytes, CD4 CD8 
splenocytes, CD8  and CD8  T cells prepared by MACS (Miltenyi Biotec)
were incubated with or without 2   104 mitomycin C-treated Meth A on
the coated membranes for 18 h at 37 C under 5% CO2. The spots were au-
tomatically counted using KS ELISPOT compact (Carl Zeiss).
Immunohistochemistry. Cryostat-frozen sections were dried and fixed
with cold acetone for 15 min at 4 C. Sections were permeabilized with phos-
phate-buffered saline containing 0.2% Tween 20, incubated with phosphate-
buffered saline containing 1% bovine serum albumin for 30 min at room tem-
perature, then with rabbit anti–mouse Foxp3 Ab and rat anti–mouse CD4
mAb (H129.19; BD Biosciences) or rat anti–CD8 (53–6.7; BD Biosciences)
for 1 h at room temperature, and subsequently with Alexa488-conjugated goat
anti–rat IgG, Alexa633-conjugated goat anti–rabbit IgG and POPO-3 iodide
(Invitrogen), and examined with an LSM 510 META microscope (Carl Zeiss).
Quantitative PCR. Real-time quantitative PCR was performed as previ-
ously described (14). To exclude amplification from genomic DNA contami-
nation, either the primers or the probes were designed to overlap splice junc-
tion. All probes but for HPRT were labeled with the fluorescent dyes
5 -FAM (6-carboxy-fluorescein) as reporter and 3 -TAMRA (6-carboxy-tetra-
methyl-rhodamine) as quencher. Probe for HPRT amplification was 5 -VIC
labeled. The sequences of forward primers, Taq Man probes (28), and reverse
primers, respectively, were as follows: Foxp3, 5 -CCCAGGAAAGACAGCA-
ACCTT-3 , 5 -ATCCTACCCACTGCTGGCAAATGGAGTC-3 , 5 -
TTCTCACAAGGCCACTTG-3 ; CD8 , 5 -GAAGCAATGCCCGTT-
CCC-3 , 5 -ACCCAGAGACCCAGAAGGGCCTGAC-3 , 5 -TGAGGG-
TGGTAAGGCTACA-3 ; CD4, 5 -CAGCATGGCAAAGGTGTATTAA-
TTAG-3 , 5 -AGGTTCGCCTTCGCAGTTTGATCGT-3 , 5 -CCCA-
TGCCCCTTTTTTGG-3 ; CD3 , 5 -CCACCTGTTCCCAACCCAG-3 ,
5 -TGAGCCCATCCGCAAAGGCC-3 , 5 -TCAGGCCAGAATACAGG-
TCCC-3 ; CD25, 5 -AGACTTCCTGCCCCATAACCA-3 , 5 -CACAG-
ACTTCCCACAACCCACAGAAACAAC-3 , 5 -TGAGCACAAATGTC-
TCCGTAC-3 ; and HPRT, 5 -TGAAGAGCTACTGTAATGATCAGT-
CAAC-3 , 5 -TGCTTTCCCTGGTTAAGCAGTACAGCCC-3 , 5 -AGC-
AAGCTTGCAACCTTAACCA-3 .
Statistical analysis. All statistical analyses were performed using the Stu-
dent’s paired t test or Fisher exact probability test.
Online supplemental material. Fig. S1 shows expression of GITR on
various tumor lines, effects of DTA-1 and PC61 on CD25 CD4  T cells in
normal mice, and effects of DTA-1 on the growth of Meth A tumors inoc-
ulated in athymic nude mice. Fig. S2 shows the ratios of Foxp3/CD3
mRNA message in DTA-1–treated or control tumors on various days after
treatment. Fig. S3 shows tumor specificity of IFN- –secreting spleen cellsJEM VOL. 202, October 3, 2005 891
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from tumor-inoculated and DTA-1–treated mice. Fig. S4 shows the speci-
ficity of rabbit anti-Foxp3 polyclonal Ab used in the present experiments.
Online supplemental material is available at http://www.jem.org/cgi/con-
tent/full/jem.20050940/DC1.
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